tiprankstipranks
Advertisement
Advertisement

EPRX Stock Latest News

Eupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX
RatingsEupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX
16d ago
EPRX
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
PremiumThe Fly
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
18d ago
EPRX
Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating
PremiumRatings
Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating
18d ago
EPRX
Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating
PremiumRatings
Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating
23d ago
EPRX
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
PremiumCompany Announcements
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
24d ago
6K
EPRX
Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
PremiumThe FlyEupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
24d ago
EPRX
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
Premium
The Fly
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
24d ago
EPRX
Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
Premium
Ratings
Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
24d ago
EPRX
Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
PremiumRatings
Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
25d ago
EPRX
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
PremiumCompany Announcements
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
29d ago
EPRX
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline
PremiumCompany Announcements
Eupraxia Pharmaceuticals Raises US$63.2 Million in February 2026 Equity Offering to Advance GI Pipeline
1M ago
6K
EPRX
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness
PremiumCompany Announcements
Eupraxia Pharmaceuticals Raises US$63.2 Million to Advance GI Pipeline and Commercial Readiness
2M ago
6K
EPRX
Eupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact
PremiumCompany AnnouncementsEupraxia Pharmaceuticals Launches Cross-Border Equity and Warrant Offering Under New Underwriting Pact
2M ago
6K
EPRX
Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00
Premium
The Fly
Eupraxia Pharmaceuticals 6.4M share Spot Secondary priced at $7.00
2M ago
EPRX
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
Premium
Company Announcements
Eupraxia Raises US$55 Million to Accelerate EP-104GI and GI Pipeline
2M ago
EPRX
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline
PremiumCompany Announcements
Eupraxia Pharmaceuticals Plans Public Offering to Fund GI Drug Pipeline
2M ago
EPRX
Eupraxia Pharmaceuticals announces common shares offering, no amount given
PremiumThe Fly
Eupraxia Pharmaceuticals announces common shares offering, no amount given
2M ago
EPRX
Eupraxia Pharmaceuticals management to meet with Cantor
PremiumThe Fly
Eupraxia Pharmaceuticals management to meet with Cantor
2M ago
EPRX
Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
PremiumThe Fly
Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
3M ago
EPRX
Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
PremiumRatingsEupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
3M ago
EPRX
Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
Premium
Company Announcements
Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
3M ago
EPRX
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
Premium
The Fly
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
3M ago
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >